PL2736888T3 - Pochodne kwasu 3-heteroaroiloamino-propionowego i ich zastosowanie jako środków farmaceutycznych - Google Patents

Pochodne kwasu 3-heteroaroiloamino-propionowego i ich zastosowanie jako środków farmaceutycznych

Info

Publication number: PL2736888T3
Authority: PL; Poland
Prior art keywords: heteroaroylamino; pharmaceuticals; propionic acid; acid derivatives; derivatives
Prior art date: 2011-07-26

Application number

PL12738473T

Other languages

English (en)

Inventor

Sven Ruf

Josef Pernerstorfer

Thorsten Sadowski

Georg Horstick

Herman Schreuder

Christian Buning

Klaus Wirth

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-26

Filing date

2012-07-25

Publication date

2016-04-29

2012-07-25 Application filed by Sanofi Sa filed Critical Sanofi Sa

2016-04-29 Publication of PL2736888T3 publication Critical patent/PL2736888T3/pl

Links

229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Furan Compounds (AREA)

PL12738473T 2011-07-26 2012-07-25 Pochodne kwasu 3-heteroaroiloamino-propionowego i ich zastosowanie jako środków farmaceutycznych PL2736888T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP11305971		2011-07-26
EP12738473.3A EP2736888B1 (en)	2011-07-26	2012-07-25	3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
PCT/EP2012/064628 WO2013014204A2 (en)	2011-07-26	2012-07-25	3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals

Publications (1)

Publication Number	Publication Date
PL2736888T3 true PL2736888T3 (pl)	2016-04-29

Family

ID=46579041

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12738473T PL2736888T3 (pl)	2011-07-26	2012-07-25	Pochodne kwasu 3-heteroaroiloamino-propionowego i ich zastosowanie jako środków farmaceutycznych

Country Status (22)

Country	Link
US (2)	US9353068B2 (pl)
EP (2)	EP3037417B1 (pl)
JP (2)	JP6021910B2 (pl)
KR (1)	KR20140049019A (pl)
CN (2)	CN105646362B (pl)
AU (2)	AU2012288842A1 (pl)
BR (1)	BR112014001518A2 (pl)
CA (1)	CA2841905A1 (pl)
CY (1)	CY1117397T1 (pl)
DK (1)	DK2736888T3 (pl)
ES (1)	ES2560381T3 (pl)
HK (1)	HK1225714A1 (pl)
HR (1)	HRP20160047T1 (pl)
HU (1)	HUE028418T2 (pl)
IL (2)	IL230126A (pl)
MX (1)	MX337173B (pl)
MY (1)	MY169319A (pl)
PL (1)	PL2736888T3 (pl)
PT (1)	PT2736888E (pl)
RU (1)	RU2014107000A (pl)
SI (1)	SI2736888T1 (pl)
WO (1)	WO2013014204A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY162786A (en) *	2011-07-26	2017-07-14	Sanofi Sa	Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals
WO2013014204A2 (en)	2011-07-26	2013-01-31	Sanofi	3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
CN107007597A (zh)	2012-05-31	2017-08-04	菲尼克斯药品股份公司	作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物的制药用途
JO3215B1 (ar)	2012-08-09	2018-03-08	Phenex Pharmaceuticals Ag	حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
WO2014053533A1 (en)	2012-10-05	2014-04-10	Sanofi	Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
WO2014154727A1 (en) *	2013-03-28	2014-10-02	Sanofi	Biaryl-propionic acid derivatives and their use as pharmaceuticals
JP6359634B2 (ja)	2013-03-28	2018-07-18	サノフイ	ビアリール−プロピオン酸誘導体および医薬品としてのその使用
WO2015188073A1 (en) *	2014-06-06	2015-12-10	Research Triangle Institute	Apelin receptor (apj) agonists and uses thereof
AU2016366310C1 (en)	2015-12-09	2021-09-09	Research Triangle Institute	Improved apelin receptor (APJ) agonists and uses thereof
ES3032633T3 (en) *	2016-10-12	2025-07-22	Res Triangle Inst	Heterocyclic apelin receptor (apj) agonists and uses thereof
KR20220054391A (ko)	2019-08-29	2022-05-02	리서치 트라이앵글 인스티튜트	아펠린 수용체 작용제에 대한 방법 및 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6080767A (en) *	1996-01-02	2000-06-27	Aventis Pharmaceuticals Products Inc.	Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
AR011515A1 (es) *	1996-12-25	2000-08-30	Agrogene Ltd	Derivado del acido aminobutirico para la proteccion de plantas de enfermedades fungosas y un metodo para proteger un cultivo contra enfermedadesfungosas por ejemplo tomates y papas contra el tizon tardio o temprano, cereales contra el mildiu polvoroso, y pepino, vides, melones contra el mildiu
DK1027328T3 (da) *	1997-10-31	2006-11-13	Aventis Pharma Ltd	Substituerede anilider
US6468977B1 (en) *	1998-03-02	2002-10-22	Apotex Inc.	Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
AU759310B2 (en) *	1998-08-20	2003-04-10	Agouron Pharmaceuticals, Inc.	Non-peptide GnRH agents, methods and intermediates for their preparation
DE19858191A1 (de) *	1998-12-17	2000-06-21	Aventis Cropscience Gmbh	4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclyl-pyrimidine und ihre Verwendung als Repellentien
US6462076B2 (en)	2000-06-14	2002-10-08	Hoffmann-La Roche Inc.	Beta-amino acid nitrile derivatives as cathepsin K inhibitors
JP2002326980A (ja) *	2001-04-27	2002-11-15	Nippon Nohyaku Co Ltd	ジアミド誘導体及び農園芸用薬剤並びにその使用方法
PL370766A1 (pl) *	2001-12-04	2005-05-30	F.Hoffmann-La Roche Ag	Podstawione 2-aminocykloalkanokarboksyamidy i ichzastosowanie jako inhibitorów proteaz cysteinowych
US20040072802A1 (en)	2002-10-09	2004-04-15	Jingwu Duan	Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
AU2003292218A1 (en)	2002-12-23	2004-07-14	Sanofi-Aventis Deutschland Gmbh	PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
US20060178433A1 (en)	2003-03-17	2006-08-10	Yasuhito Yamamoto	3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto
EP1493740A1 (fr) *	2003-07-03	2005-01-05	Warner-Lambert Company LLC	Dérivés de 5-fluoro-thiophene, leur procédé de preparation, les compositions pharmaceutiques les contenant et leur utilisation comme inhibiteurs de métalloprotéinases
EP1493739A1 (fr) *	2003-07-03	2005-01-05	Warner-Lambert Company LLC	Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US7115646B2 (en) *	2003-10-08	2006-10-03	Bristol Myers Squibb, Co.	Cyclic diamines and derivatives as factor Xa inhibitors
JP2005145839A (ja)	2003-11-12	2005-06-09	Japan Science & Technology Agency	新規なカテプシンａ阻害剤
TW200526641A (en) *	2003-12-26	2005-08-16	Daiichi Seiyaku Co	Amidopyrazole derivatives
JP5123668B2 (ja)	2005-01-10	2013-01-23	エグゼリクシス，インコーポレイテッド	医薬品としての複素環カルボキサミド化合物
AU2007226673A1 (en) *	2006-03-10	2007-09-20	Jenrin Discovery	Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
WO2008124838A1 (en) *	2007-04-10	2008-10-16	University Of Maryland, Baltimore	Compounds that inhibit human dna ligases and methods of treating cancer
JPWO2009028280A1 (ja) *	2007-08-29	2010-11-25	三井化学アグロ株式会社	ピラゾールカルボン酸誘導体及びその製造方法、並びに殺菌剤
US8133904B2 (en) *	2007-09-07	2012-03-13	Jenrin Discovery, Inc.	Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
AU2008345225A1 (en) *	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
EP2238127B1 (en)	2007-12-26	2012-08-15	Sanofi	Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en)	2007-12-26	2012-08-22	Sanofi	Heterocyclic pyrazole-carboxamides as p2y12 antagonists
JP5411927B2 (ja) *	2008-05-06	2014-02-12	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
US7863309B2 (en) *	2008-07-24	2011-01-04	Theravance, Inc.	Dual-acting antihypertensive agents
PL2435409T3 (pl) *	2009-05-28	2015-01-30	Novartis Ag	Podstawione pochodne aminopropionowe jako inhibitory neprylizyny
US7956054B2 (en) *	2009-07-07	2011-06-07	Theravance, Inc.	Dual-acting pyrazole antihypertensive agents
EP2456762B1 (en) *	2009-07-22	2013-10-16	Theravance, Inc.	Dual-acting oxazole antihypertensive agents
UY33200A (es) *	2010-01-26	2011-08-31	Sanofi Aventis	Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
ES2602835T3 (es) *	2011-05-17	2017-02-22	Waterdiam Sàrl	Método para tratar cítricos después de la cosecha
ES2653215T3 (es) *	2011-05-31	2018-02-06	Theravance Biopharma R&D Ip, Llc	Inhibidores de neprilisina
WO2013014204A2 (en)	2011-07-26	2013-01-31	Sanofi	3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals

2012
- 2012-07-25 WO PCT/EP2012/064628 patent/WO2013014204A2/en not_active Ceased
- 2012-07-25 HR HRP20160047TT patent/HRP20160047T1/hr unknown
- 2012-07-25 EP EP15190731.8A patent/EP3037417B1/en not_active Not-in-force
- 2012-07-25 SI SI201230439T patent/SI2736888T1/sl unknown
- 2012-07-25 CA CA2841905A patent/CA2841905A1/en not_active Abandoned
- 2012-07-25 CN CN201511021647.3A patent/CN105646362B/zh not_active Expired - Fee Related
- 2012-07-25 JP JP2014522086A patent/JP6021910B2/ja not_active Expired - Fee Related
- 2012-07-25 PT PT127384733T patent/PT2736888E/pt unknown
- 2012-07-25 ES ES12738473.3T patent/ES2560381T3/es active Active
- 2012-07-25 EP EP12738473.3A patent/EP2736888B1/en not_active Not-in-force
- 2012-07-25 MY MYPI2013004643A patent/MY169319A/en unknown
- 2012-07-25 RU RU2014107000/04A patent/RU2014107000A/ru not_active Application Discontinuation
- 2012-07-25 AU AU2012288842A patent/AU2012288842A1/en not_active Abandoned
- 2012-07-25 DK DK12738473.3T patent/DK2736888T3/da active
- 2012-07-25 BR BR112014001518A patent/BR112014001518A2/pt not_active IP Right Cessation
- 2012-07-25 CN CN201280046863.1A patent/CN103827097B/zh not_active Expired - Fee Related
- 2012-07-25 KR KR1020147004756A patent/KR20140049019A/ko not_active Withdrawn
- 2012-07-25 MX MX2014000598A patent/MX337173B/es active IP Right Grant
- 2012-07-25 PL PL12738473T patent/PL2736888T3/pl unknown
- 2012-07-25 HU HUE12738473A patent/HUE028418T2/en unknown
- 2012-07-26 US US13/559,401 patent/US9353068B2/en not_active Expired - Fee Related
2013
- 2013-12-23 IL IL230126A patent/IL230126A/en not_active IP Right Cessation
2016
- 2016-02-03 CY CY20161100093T patent/CY1117397T1/el unknown
- 2016-04-27 US US15/140,350 patent/US9751858B2/en not_active Expired - Fee Related
- 2016-09-30 JP JP2016192793A patent/JP6360534B2/ja not_active Expired - Fee Related
- 2016-12-06 HK HK16113874.6A patent/HK1225714A1/zh unknown
2017
- 2017-01-31 IL IL250370A patent/IL250370A0/en unknown
- 2017-06-02 AU AU2017203739A patent/AU2017203739A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN105646362A (zh)	2016-06-08
MX337173B (es)	2016-02-16
EP3037417A2 (en)	2016-06-29
ES2560381T3 (es)	2016-02-18
AU2012288842A1 (en)	2014-02-06
BR112014001518A2 (pt)	2017-02-14
MX2014000598A (es)	2014-02-27
EP2736888B1 (en)	2015-11-04
HK1192559A1 (en)	2014-08-22
DK2736888T3 (da)	2016-02-01
IL250370A0 (en)	2017-03-30
EP2736888A2 (en)	2014-06-04
SI2736888T1 (sl)	2016-02-29
WO2013014204A2 (en)	2013-01-31
HRP20160047T1 (hr)	2016-02-12
CY1117397T1 (el)	2017-04-26
JP2014525912A (ja)	2014-10-02
AU2017203739A1 (en)	2017-06-22
JP6360534B2 (ja)	2018-07-18
HUE028418T2 (en)	2016-12-28
MY169319A (en)	2019-03-21
PT2736888E (pt)	2016-02-17
JP6021910B2 (ja)	2016-11-09
WO2013014204A3 (en)	2013-04-04
JP2017031199A (ja)	2017-02-09
CN105646362B (zh)	2019-07-05
US9751858B2 (en)	2017-09-05
IL230126A0 (en)	2014-03-06
US20130053416A1 (en)	2013-02-28
US20160237060A1 (en)	2016-08-18
IL230126A (en)	2017-02-28
US9353068B2 (en)	2016-05-31
KR20140049019A (ko)	2014-04-24
CN103827097A (zh)	2014-05-28
RU2014107000A (ru)	2015-09-10
HK1225714A1 (zh)	2017-09-15
CA2841905A1 (en)	2013-01-31
CN103827097B (zh)	2016-03-16
EP3037417B1 (en)	2019-05-22
EP3037417A3 (en)	2016-10-12

Publication	Publication Date	Title
IL250370A0 (en)	2017-03-30	Propionic acid derivatives substituted with heteroaroylamino in position 3 and their use as pharmaceuticals
EP2668177A1 (en)	2013-12-04	Substituted pyridinyl-pyrimidines and their use as medicaments
AP2014007658A0 (en)	2014-05-31	Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
IL235425B (en)	2018-07-31	History of lysine-glutamic acid di-peptide
IL249826A0 (en)	2017-02-28	Propionic acid derivatives converted in 3-heteroylamino and their use in pharmaceutical preparations
ZA201204414B (en)	2013-02-27	Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
IL236965B (en)	2019-03-31	Derivatives of 5-aminolevulinic acid and uses thereof
ZA201503171B (en)	2016-11-30	Modified hyaluronic acid derivatives and use thereof
SG11201406942SA (en)	2014-11-27	Trans-2-decenoic acid derivative and drug containing same
IL232809A (en)	2017-05-29	Carboxamides are preserved in position 2 isothiazolopyridine-2-carboxamides and used as drugs
IL231096A0 (en)	2014-03-31	2-converted thiazoles (chroman-6-yloxy) and their use as pharmaceutical preparations
PH12014500542A1 (en)	2014-04-21	Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
IL240447A (en)	2017-07-31	Propionic Acid-Baryl Acid Derivatives and Their Use as Pharmaceutical Preparations
IL240422B (en)	2018-12-31	Bi-aryl derivatives of propionic acid and their use as medicinal preparations